ReviewClinical rheumatology2018
Advances in the diagnosis and treatment of Sjogren's syndrome.
Review in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren's Syndrome.Frontiers in immunology · 2022Pooled it
- Diagnostic performance of serology against histologic assessment to diagnose Sjogren's syndrome: a systematic review.Clinical rheumatology · 2021Pooled it
- Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study.Clinical ophthalmology (Auckland, N.Z.) · 2021Trial
- NRIP1 disrupts ERα signal in Sjögren's disease via AQP5 suppression and MYC-driven salivary dysfunction.Experimental & molecular medicine · 2026Article
- Primary sjögren's syndrome among patients with cerebral infarction.Scientific reports · 2025Article
- Serology and histology in Sjögren's syndrome diagnosis: a retrospective accuracy study.Clinical rheumatology · 2025Article
- G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.Acta pharmacologica Sinica · 2024Article
- Laboratory features and pharmacological management of early and late-onset primary Sjögren's syndrome.Rheumatology international · 2024Article
- A Smartphone App to Support Self-Management for People Living With Sjögren's Syndrome: Qualitative Co-Design Workshops.JMIR human factors · 2024Article
- Satellite Glial Cells in Human Disease.Cells · 2024Review
- Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren's Syndrome: An Updated Review of Current Insights and Future Perspectives.Journal of clinical medicine · 2024Review
- Advances in Sjögren's Syndrome Dry Eye Diagnostics: Biomarkers and Biomolecules beyond Clinical Symptoms.Biomolecules · 2024Review
- The decreased of peripheral blood natural killer cell is associated with serum IL-2 level in the renal tubular acidosis in patients with primary sjogren's syndrome.BMC immunology · 2023Article
- Is Chinese herbal formula (nourishing Yin therapy) effective and well tolerated as an adjunct medication to hydroxychloroquine in the treatment of primary Sjögren's syndrome? A meta-analysis of randomised controlled trials.Therapeutic advances in chronic disease · 2022Article
- Decoding the Mechanism of CheReCunJin Formula in Treating Sjögren's Syndrome Based on Network Pharmacology and Molecular Docking.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Sjögren's Syndrome and Viral Infections.Rheumatology and therapy · 2021Review
- CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Increased Risk of Sjögren's Syndrome in Patients with Obsessive-Compulsive Disorder: A Nationwide Population-Based Cohort Study.International journal of environmental research and public health · 2021Article
- Publication activity in the field of Sjögren's syndrome: a ten-year Web of Science based analysis.Rheumatology international · 2021Article
- Deciphering potential pharmacological mechanism of Sha-Shen-Mai-Dong decoction on primary Sjogren's syndrome.BMC complementary medicine and therapies · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Sjogren's syndrome (SS) is a systemic autoimmune disease that primarily affects the exocrine glands, resulting in dryness of the eyes and mouth due to lymphocytic infiltration of the salivary and lacrimal glands along with arthritis, kidney, liver, and lung involvement, chronic fatigue, musculoskeletal pain, vasculitis, and so on. Considerable advance has been made for the classification and treatment of primary SS in the past few years. This article reviews the recent classification criteria for primary SS and briefly discusses the conventional and novel therapies of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.